Norovirus Vaccine Trials: A Potential Breakthrough for Winter Vomiting Bug
A new norovirus vaccine by Moderna will be tested on 25,000 adults over two years across multiple countries to combat the virus that causes widespread vomiting and diarrhea. The trial aims to reduce hospitalizations and healthcare costs by providing immunity through an mRNA vaccine targeting three strains. If successful, the vaccine could eventually protect children.
A novel vaccine developed by Moderna is set to be tested on 25,000 adults, primarily over the age of 60, across more than six countries over the next two years.
This trial, involving the UK Government and the National Institute for Health and Care Research (NIHR), could lead to the first-ever licensed vaccine against norovirus, a highly contagious virus causing vomiting and diarrhea.
The UK faces significant impacts from norovirus, with nearly four million infections each year and the NHS incurring costs of around £100 million annually.
The virus particularly affects vulnerable groups like older adults and healthcare workers.
The mRNA-based vaccine targets three common strains of the virus and aims to reduce hospitalizations and the financial burden on healthcare systems.
If proven at least 65% effective, it could eventually extend to children.
Mobile units will facilitate vaccine distribution, and 27 NHS hospitals in England, Scotland, and Wales will participate in the trial.
This trial also seeks to establish the vaccine's efficacy, duration of protection, and any side effects.
This trial, involving the UK Government and the National Institute for Health and Care Research (NIHR), could lead to the first-ever licensed vaccine against norovirus, a highly contagious virus causing vomiting and diarrhea.
The UK faces significant impacts from norovirus, with nearly four million infections each year and the NHS incurring costs of around £100 million annually.
The virus particularly affects vulnerable groups like older adults and healthcare workers.
The mRNA-based vaccine targets three common strains of the virus and aims to reduce hospitalizations and the financial burden on healthcare systems.
If proven at least 65% effective, it could eventually extend to children.
Mobile units will facilitate vaccine distribution, and 27 NHS hospitals in England, Scotland, and Wales will participate in the trial.
This trial also seeks to establish the vaccine's efficacy, duration of protection, and any side effects.
